A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy

Reumatismo

Volumn 65, Issue 6, 2013, Pages 298-301

  Notarnicola, Antonella ^a   Iannone, F ^a   Lopalco, G ^a   Covelli, M ^a   Lapadula, G ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Anti TNF ; False occult hepatitis B infection; HBV DNA by real time PCR; Rheumatic diseases

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; VIRUS DNA; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; HEPATITIS B CORE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DNA DETERMINATION; FALSE OCCULT HEPATITIS B VIRUS INFECTION; FOLLOW UP; HEPATITIS B; HUMAN; MALE; MIDDLE AGED; PSORIATIC ARTHRITIS; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; TREATMENT DURATION; VIRUS REACTIVATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ARTHRITIS, PSORIATIC; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HEPATITIS B VIRUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84896467510     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2013.727     Document Type: Article

References (15)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30: 2212-9.
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009; 49: S45-55.
3. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007; 39: 397-408.
4. Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, et al. The use of molecular assays in the management of viral hepatitis. Dig Liver Dis. 2008; 40: 395-404.
5. Mastroianni CM, Lichtner M, Citton R, Del BC, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011; 17: 3881-7.
6. Launay O, Masurel J, Servant-Delmas A, Basse-Guerineau AL, Meritet JF, Laperche S, et al. High levels of serum hepatitis B virus DNA in patients with 'anti-HBc alone': role of HBsAg mutants. J Viral Hepat. 2011; 18: 721-9.
7. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013; 72: ii2-34.
8. Zhuang H. [Updates of EASL clinical practice guidelines: management of chronic hepatitis B virus infection]. Zhonghua Gan Zang Bing Za Zhi. 2012; 20: 427-9.
9. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-85.
10. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010; 62: 749-54.
11. Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis. 2009; 1(3): e2009025.
12. Bazhenov AI, Konopleva MV, El'gort DA, Fel'dsherova AA, Budnitskaia PZ, Nikitina NI, et al. [Algorithm of serologic screening and assessment of prevalence of serologically meaningful mutations of HBsAg in hepatitis B virus carriers]. Zh Mikrobiol Epidemiol Immunobiol. 2007; 6: 30-7.
13. Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, et al. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigenpositive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl. 2010; 16: 885-94.
14. Roque-Afonso AM, Ferey MP, Belkhiri D, Dussaix E. [HBs antigen mutants: prevalence, clinical and diagnostic implications]. Pathol Biol (Paris). 2005; 53: 563-8.
15. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001; 44: 339-42.